In summary, our results provide new evidence for the Y1 receptor acting in a counter-regulatory fashion in insulin release in vivo and suggest that impaired Y1 receptor signaling in the pancreas may play a causal role in the development of metabolic diseases such as obesity. The gene discussed is INS; the disease is metabolic disease.